Sens. Capito, Collins Urge CMS to Ensure Alzheimer's Coverage Decision Does Not Restrict Access, Impede Research
March 02, 2022
March 02, 2022
WASHINGTON, March 2 -- Sen. Shelley Moore Capito, R-West Virginia, issued the following news release:
In January, the Centers for Medicare and Medicaid Services (CMS) released a draft National Coverage Determination (NCD) that proposes to restrict coverage of a new class of Alzheimer's treatments, monoclonal antibodies that target amyloid plaque, to Alzheimer's patients who are enrolled in qualifying clinical trials.
In response to this coverage decision, U.S. . . .
In January, the Centers for Medicare and Medicaid Services (CMS) released a draft National Coverage Determination (NCD) that proposes to restrict coverage of a new class of Alzheimer's treatments, monoclonal antibodies that target amyloid plaque, to Alzheimer's patients who are enrolled in qualifying clinical trials.
In response to this coverage decision, U.S. . . .